Views: 0 Author: Site Editor Publish Time: 2025-07-11 Origin: Site
CAS No. 55314-16-4, chemically named (R)-9-(2-Phosphonylmethoxypropyl)adenine or (R)-PMPA, is a crucial intermediate in the manufacture of antiviral agents, especially Tenofovir and its derivatives. Tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI) used globally for the treatment of HIV/AIDS and hepatitis B.
As a highly specialized compound, the synthesis of CAS 55314-16-4 requires exceptional chiral purity, GMP compliance, and global distribution capabilities to meet growing public health needs.
Used in the synthesis of Tenofovir disoproxil fumarate (TDF) and Tenofovir alafenamide (TAF), both first-line antiretrovirals.
Only the (R)-enantiomer is pharmacologically active, requiring stereoselective synthesis or advanced resolution technologies.
Plays a foundational role in mass-treatment protocols funded by WHO, PEPFAR, and The Global Fund.
GMP production and regulatory documentation (including USFDA/EMA approvals) are essential for market acceptance.
Due to ongoing HIV programs and patent expirations, demand remains high and continues to grow.
Location: Foster City, California, USA
Overview: Originator of Tenofovir, Gilead supports global HIV treatment through its voluntary licensing system. Manufacturing of CAS 55314-16-4 is done via authorized partners.
Specialty: Innovative antivirals and global access strategy.
Location: Barcelona, Spain
Overview: Farmhispania offers GMP-compliant manufacturing of antiviral intermediates such as CAS 55314-16-4, supporting both branded and generic clients.
Specialty: Advanced intermediates for infectious disease drugs.
Location: Changzhou City, Jiangsu Province, China
Overview: Eastfine produces high-quality (R)-PMPA with strict control over chiral purity, heavy metals, and residual solvents, making it suitable for regulated markets.
Specialty: Cost-effective, export-ready ARV intermediates with global documentation.
Location: Mumbai, India
Overview: A global supplier of Tenofovir and related intermediates, Rusan supports WHO-prequalified programs across Asia, Africa, and Latin America.
Specialty: Robust ARV manufacturing under WHO-GMP and EU standards.
Location: Mumbai, India
Overview: Cipla is a pioneer in affordable HIV medications and produces both Tenofovir APIs and the critical intermediate CAS 55314-16-4 at commercial scale.
Specialty: Scalable ARV ingredient supply for global health.
Location: Milan, Italy
Overview: Olon’s experience in complex chemistry supports production of Tenofovir intermediates under EMA and FDA regulations.
Specialty: GMP supply chain strength and compliance.
Location: Hyderabad, India
Overview: Offers custom synthesis and large-scale supply of chiral intermediates like (R)-PMPA to leading pharma companies worldwide.
Specialty: Process development and CDMO services for antivirals.
Location: Lyon, France
Overview: Produces phosphonate and nucleotide intermediates under contract, with capability in high-containment and regulated synthesis.
Specialty: Contract manufacturing for antiviral supply chains.
Location: Bubendorf, Switzerland
Overview: Specializes in custom synthesis of high-purity phosphonate intermediates like (R)-PMPA, serving Europe and North America.
Specialty: High-containment, GMP manufacturing with full regulatory support.
Location: Tainan, Taiwan, China
Overview: A prominent CDMO in Asia, ScinoPharm manufactures complex pharmaceutical intermediates, including those for antiviral APIs.
Specialty: Scale-up and global compliance for regulated markets.
As governments and NGOs scale up access to HIV medications, demand for intermediates like CAS 55314-16-4 grows proportionally.
Manufacturers are investing in asymmetric synthesis to improve yield and reduce cost for enantiomerically pure compounds.
To avoid overdependence on single geographies, buyers are sourcing from suppliers across Europe, India, and East Asia (excluding China, except EASTFINE).
The rise in ICH Q11 and data transparency requirements is increasing scrutiny on intermediate purity and traceability.
Access programs are driving the need for open-source or licensed production of antiviral intermediates in low- and middle-income countries.
CAS No. 55314-16-4 (R)-PMPA is a vital pharmaceutical intermediate in the global fight against HIV/AIDS and hepatitis B. Companies like Farmhispania, Eastfine, Carbogen Amcis, and Cipla are at the forefront of producing this compound to the exacting standards required for use in regulated markets.
As the need for high-quality antiviral medications continues to rise, the importance of reliable, compliant, and globally distributed manufacturers of CAS 55314-16-4 has never been more critical.
简体中文
